Verdict: GHK-Cu is a copper-binding tripeptide with a few small human trials, all topical, in skin and wounds. BPC-157 is a synthetic 15-amino-acid peptide supported mainly by rodent studies and three tiny uncontrolled human reports. Neither is FDA-approved. BPC-157 is prohibited in sport.
The evidence gap runs in an unexpected direction. GHK-Cu has an older randomized trial in diabetic foot ulcers (Mulder 1994) but almost no data on tendons or joints. BPC-157 has many rat studies on tendons, gut and wounds but no published controlled human trial (McGuire 2025). The FDA says it has limited human safety data for both peptides as compounded drugs (FDA).
| Item | GHK-Cu | BPC-157 |
|---|---|---|
| US FDA status | Not an approved drug (Mendias 2026) | Not approved for any use (USADA) |
| Compounding (503A/503B) | Withdrawn from Category 2 by nominators; on no bulks list (FDA) PCAC voted 8–6 (1 abstention) on 2026-07-23 to recommend 503A listing; advisory only, no FDA rule yet (FDA PCAC meeting; counts as reported by trade press) | Withdrawn from Category 2; reviewed by FDA advisers July 2026, no rule yet (FDA PCAC) |
| WADA 2026 | Cosmetic GHK listed as not prohibited; other uses not addressed (USADA) | Prohibited, S0 non-approved substances (USADA) |
| Strongest evidence | Human RCT, topical (diabetic ulcers) | Human case series, uncontrolled (n=16) |
| Human trials | Published RCTs incl. 1994 and 2006; 1 registered, not yet recruiting: NCT07706361 | 3 pilot reports (n=16, 12, 2); 3 registered, none with posted results (NCT02637284, NCT07752381, NCT07803250) |
| Last checked | 2026-10-18 | 2026-09-30 |
Key points:
- GHK was first identified in 1973 as an activity in human albumin and binds copper strongly (Pickart 2012); BPC-157 is a synthetic peptide its developers describe as stable in human gastric juice (Sikiric 2012).
- The GHK-Cu human trials found used topical products; the published BPC-157 human reports placed it into the knee, the bladder or a vein (Lee 2021; Lee 2024; Lee 2025).
- A 2026 systematic review of GHK-Cu in aesthetic medicine found only two randomized trials (Mokhtar 2026).
- About 35% of GHK-Cu literature comes from one author pair (Najafi 2026), and all three BPC-157 human reports share one first author, which limits independent confirmation.
- The two peptides have never been tested together in a controlled human study.
GHK-Cu vs BPC-157 at a glance
| Feature | GHK-Cu | BPC-157 |
|---|---|---|
| What it is | Tripeptide (glycyl-histidyl-lysine) bound to copper | Synthetic 15-amino-acid peptide |
| Origin | First identified in human albumin, 1973 | Gastric peptide research; stable in gastric juice |
| Class | Copper peptide; cosmetic ingredient | Unapproved research peptide |
| Mechanism studied | Collagen synthesis, vessel growth (lab, animal) | Fibroblast migration, VEGFR2 signaling (lab, animal) |
| Main research focus | Skin aging, wounds | Tendon, gut, wound healing |
| Human evidence | RCTs incl. 1994 and 2006 | 3 uncontrolled pilots (2021, 2024, 2025) |
| FDA approval | None | None |
| WADA | Cosmetic GHK not prohibited | Prohibited (S0) |
| Routes in human studies | Topical gel or cream | Intra-articular, intravesical, intravenous |
| Timelines in studies | Rat ligament gain at 6 weeks, gone by 12 | Rat tendon changes within 14 days |
| Main safety concerns | Immunogenicity and impurities if injected; little human data | No human safety data beyond pilots; unregulated products |
What is GHK-Cu?
GHK-Cu is a three-amino-acid peptide, glycyl-L-histidyl-L-lysine, carried as a complex with copper. It was discovered in 1973 as an activity in human albumin, a blood protein, and has a high affinity for copper (Pickart 2012). Most of what is known about it comes from lab and animal work reviewed by its discoverer’s group (Pickart 2018). It is a common cosmetic skin ingredient and has been tested in humans as a topical gel for diabetic ulcers (Mulder 1994). It is not an approved drug. For compounded injectable versions, the FDA notes “limited data in humans” (FDA).
What is BPC-157?
BPC-157 (“body protection compound”) is a synthetic 15-amino-acid peptide, a pentadecapeptide, that its developers describe as stable in human gastric juice. Nearly all its research is in rats and mice, much of it from one group in Zagreb (Sikiric 2012). A 2025 review counted only three human pilot studies, with no adverse effects reported but no rigorous, large trials (McGuire 2025). It is not approved anywhere and is prohibited in sport (USADA). Its best-known pairing is with TB-500, covered in BPC-157 vs TB-500.
How they work differently
- GHK-Cu: in fibroblast cultures, the copper complex raised collagen production, with the largest effect at a concentration of 1 nanomolar [Lab] (Maquart 1988).
BPC-157: in rat tendon fibroblasts it increased cell migration and survival through the FAK-paxillin signaling pathway, without changing cell division [Lab] (Chang 2011). - GHK-Cu: packaged in liposomes, it raised endothelial (blood-vessel lining) cell proliferation by 33.1% and enhanced new vessel growth in mouse scald wounds [Lab, Animal] (Wang 2017).
BPC-157: it activated the VEGFR2-Akt-eNOS pathway, a growth-factor receptor route for vessel formation, and sped blood-flow recovery in rat limb ischemia [Lab, Animal] (Hsieh 2017). - GHK-Cu: its human trials used skin-applied products, so the tested effects are local to the skin or wound (Miller 2006).
BPC-157: its human reports placed the peptide into the knee, the bladder or a vein (Lee 2021; Lee 2024; Lee 2025).
Both peptides affect blood-vessel growth in lab models. A 2026 review of unregulated peptides lists pathological blood-vessel growth and cancer development among the risks of concern (Moiz 2026). No human study has measured either risk for these two peptides.
Evidence head-to-head
Each cell gives the best evidence found in a PubMed and ClinicalTrials.gov search on 2026-09-30, with its level.
| Outcome | GHK-Cu best evidence | BPC-157 best evidence |
|---|---|---|
| Chronic skin ulcers | Human RCT (multicenter; n not in abstract): diabetic ulcers 98.5% vs 60.8% median closure (Mulder 1994) | Animal: faster healing in hyperglycemic rats with PL 14736, a code name for BPC-157 (Seveljević-Jaran 2006; Klicek 2008) |
| Burns, acute wounds | Animal: mouse scald wounds (Wang 2017) | Animal: mouse burn wounds (Mikus 2001) |
| Skin after laser resurfacing | Human RCT (n=13): no objective difference; higher satisfaction (Miller 2006) | No studies found |
| Wrinkles, skin aging | Systematic review: 2 RCTs; less wrinkle volume and depth vs controls (Mokhtar 2026) | No studies found |
| Tendon, ligament | Animal (n=72 rats): transient ACL graft gain (Fu 2015) | Animal: rat Achilles healing (Staresinic 2003; Krivic 2006) |
| Knee pain | No studies found | Human case series (n=16), uncontrolled (Lee 2021) |
| Bladder pain (interstitial cystitis) | No studies found | Human pilot (n=12), uncontrolled (Lee 2024) |
| Gut inflammation | No studies found | Animal: rat colitis (Klicek 2013) |
| Human safety | Topical use in RCTs; injectable use “limited data” (FDA) | Human pilot (n=2): no adverse effects (Lee 2025) |
Three caveats shape this table. First, the strongest GHK-Cu result is from 1994, and its abstract does not report how many patients took part. It also reported fewer infections (7% vs 34%) in plantar ulcers treated with the GHK-Cu gel immediately after debridement, but our search found no published replication [Human RCT] (Mulder 1994). Second, independence is thin on both sides: a 2026 systematic review found that about 35% of GHK-Cu literature was written by the Pickart and Margolina group (Najafi 2026), and the three BPC-157 human reports share the same first author. Third, the uncontrolled BPC-157 reports cannot separate a drug effect from natural recovery or placebo. A 2026 scoping review of sports-medicine peptides, which covered both, found that 67% of the publications used animal models and that human data showed “modest improvements at best” [Review] (Tewari 2026).
One tendon result cuts against BPC-157’s reputation. In a 2026 rat Achilles study, the abstract reports significant strength and tissue-score gains for TB-500 and one tissue score for the TB-500 plus BPC-157 combination, and does not report a significant difference for BPC-157 alone [Animal, n=32] (Biçer 2026).
Which fits which goal?
- Skin wounds and ulcers: GHK-Cu has more evidence, including a randomized human trial of a topical gel (Mulder 1994). BPC-157 has only animal wound data (Mikus 2001).
- Cosmetic skin aging: GHK-Cu has more evidence, though a 2026 review called for “larger, controlled trials” (Mokhtar 2026). No BPC-157 study was found.
- Tendons, ligaments and muscle: BPC-157 has more animal studies (Staresinic 2003); its registered human trials have no posted results, among them one after rotator cuff repair surgery (NCT07803250). GHK-Cu has one rat ligament study with a short-lived effect (Fu 2015).
- Gut: BPC-157 has rat colitis data (Klicek 2013); no GHK-Cu gut study was found.
More evidence is not proof of benefit in people. For any injury or skin condition, a clinician is the person to decide what fits.
Can they be combined?
The two are sold together in blends such as GLOW, which adds TB-500; the KLOW vs GLOW vs GHK-Cu comparison covers those products. Recent reviews discuss the two side by side as separate agents (Tewari 2026). No controlled human study has tested the combination, and no animal study of this specific pair turned up in our PubMed search.
Safety and regulatory status
United States: FDA
Neither peptide is an FDA-approved drug (Mendias 2026). Both were in the FDA’s Category 2 list of compounding substances with significant safety risks until their nominators withdrew them; the page, updated 2026-04-22, now lists both as withdrawn (FDA). Withdrawal is not approval. On BPC-157, the FDA wrote that it “lacks sufficient information to know whether the drug would cause harm when administered to humans.” On GHK-Cu, it wrote that compounded injectables “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities.” Immunogenicity means provoking an immune reaction against the product.
FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 for ulcerative colitis on 2026-07-23; GHK-Cu was not on the agenda (FDA PCAC). The committee advises the FDA; a substance joins the 503A bulks list only through notice-and-comment rulemaking (FDA 503A). USADA states there is currently “no legal basis to include BPC-157 in any compounded medication” (USADA).
Sport: WADA and USADA
The 2026 WADA Prohibited List has been in force since January 1, 2026 (USADA). BPC-157 is prohibited under S0, non-approved substances. USADA lists cosmetic “Tripeptide-1 (GHK, non-palmitoylated)” as not prohibited, does not address injected GHK-Cu, and warns that a prohibited peptide is just as prohibited in a topical product as in an injected one (USADA cosmetics). USADA tells athletes to check each product on its Global DRO database.
Product quality
Outside topical cosmetics, both peptides mostly circulate as unregulated products. Reviews from 2026 describe product contamination, manufacturing impurities and inaccurate content (Moiz 2026) and “products of uncertain identity, purity, potency, sterility, and safety” (Hailu 2026). No established human dose exists outside approved labels, and neither peptide has one.
How long do effects take in studies?
- GHK-Cu, rat ACL reconstruction: knee laxity was lower than with saline at 6 weeks, but the difference had disappeared by 12 weeks [Animal, n=72] (Fu 2015).
- GHK-Cu, mouse scald wounds: healing time with liposomal GHK-Cu shortened to 14 days [Animal] (Wang 2017).
- BPC-157, rat Achilles tendon: strength and function measures improved across days 1 to 14 [Animal] (Staresinic 2003).
- BPC-157, mouse burns: poor re-epithelialization was reversed at two weeks [Animal] (Mikus 2001).
- BPC-157, rotator cuff repair: a human trial planned for 2027 measures strength at 12 weeks and 5 months (NCT07803250).
What users report
What follows are unverified self-reports from people who usually bought unregulated products; they are not evidence. People who post about GHK-Cu on forums and social media mostly discuss skin: many describe smoother texture, fewer fine lines or fuller-looking hair after several weeks of topical use, while others report no visible change. Among those who describe injecting GHK-Cu, a recurring complaint is stinging, redness or a lump at the site. People who post about BPC-157 most often describe less tendon, joint or gut discomfort, with timelines ranging from days to several weeks; a sizeable share say they noticed nothing. Common complaints for both include cost, inconsistent product quality and not knowing what a product actually contains. Frequent arguments center on whether reported effects come from the peptide or from rest and natural healing, whether BPC-157 raises cancer risk through blood-vessel growth, and whether swallowing BPC-157 or applying either peptide to the skin does anything at all.
Frequently asked questions
Is GHK-Cu or BPC-157 better for skin?
GHK-Cu has more skin evidence. It has small randomized human trials of topical products, while BPC-157 has only animal wound studies. That still makes GHK-Cu’s skin evidence modest: a 2026 systematic review found just two randomized trials in aesthetic use and called for larger, controlled studies with standardized formulations (Mokhtar 2026).
Is BPC-157 or GHK-Cu FDA approved?
No. Neither peptide is an FDA-approved drug. Both were removed from the FDA’s Category 2 compounding list because their nominators withdrew them, not because the FDA cleared them. The FDA’s own entry says it lacks enough information to know whether BPC-157 would cause harm in humans (FDA).
Can athletes use GHK-Cu or BPC-157?
BPC-157 is prohibited under WADA’s S0 class for non-approved substances. For GHK-Cu, USADA lists cosmetic non-palmitoylated GHK as not prohibited but does not address injected forms, and it tells athletes to check each product on Global DRO (USADA).
Are GHK-Cu and BPC-157 the same kind of peptide?
No. GHK-Cu is a three-amino-acid peptide first found in human albumin that carries copper, while BPC-157 is a synthetic 15-amino-acid sequence from gastric peptide research. Both affect blood vessels and fibroblasts in lab models, through different signaling routes (Pickart 2012).
Has anyone tested GHK-Cu and BPC-157 together?
As covered above, no combination study, human or animal, has been published; the registered human trials each test one peptide alone (NCT07706361; NCT07803250). Blends that contain both, such as GLOW, rest on separate studies of each ingredient.
References
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Updated 2026-04-22. fda.gov
- US Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act. Updated 2026-05-14. fda.gov
- US Food and Drug Administration. July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- US Anti-Doping Agency. BPC-157: peptide prohibited. usada.org
- US Anti-Doping Agency. Peptides, growth hormones and cosmetics. usada.org
- US Anti-Doping Agency. Prohibited List. usada.org
- Pickart L, Vasquez-Soltero JM, Margolina A. 2012. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. PubMed 22666519
- Pickart L, Margolina A. 2018. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. PubMed 29986520
- Maquart FX, Pickart L, Laurent M, et al. 1988. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. PubMed 3169264
- Mulder GD, Patt LM, Sanders L, et al. 1994. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. PubMed 17147644
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. 2006. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. PubMed 16847171
- Mokhtar J, Mohamad B, Haddad J, et al. 2026. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthet Surg J. PubMed 42619529
- Najafi N, Maatouk H, Vardanyan KG, et al. 2026. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Arch Intern Med Res. PubMed 42787770
- Fu SC, Cheuk YC, Chiu WY, et al. 2015. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. PubMed 25731775
- Wang X, Liu B, Xu Q, et al. 2017. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. PubMed 28370978
- Sikiric P, et al. 2012. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. PubMed 22300085
- Staresinic M, Sebecic B, Patrlj L, et al. 2003. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. PubMed 14554208
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. 2006. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. PubMed 16583442
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. 2011. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. PubMed 21030672
- Hsieh MJ, et al. 2017. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. PubMed 27847966
- Mikus D, et al. 2001. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. PubMed 11718984
- Seveljević-Jaran D, et al. 2006. Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats. Skin Pharmacol Physiol. PubMed 16785777
- Klicek R, et al. 2008. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. PubMed 18818478
- Klicek R, Kolenc D, Suran J, et al. 2013. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. PubMed 24304574
- Biçer O, Adanir O, Güleryüz Y, et al. 2026. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. PubMed 42542926
- Lee E, Padgett B. 2021. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. PubMed 34324435
- Lee E, Walker C, Ayadi B. 2024. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. PubMed 39325560
- Lee E, Burgess K. 2025. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. PubMed 40131143
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. 2025. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. PubMed 40789979
- Tewari K, Liu TP, Im C, et al. 2026. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. PubMed 42578445
- Mendias CL, Awan TM. 2026. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. PubMed 41966639
- Moiz A, O’Keefe EL, O’Keefe JH. 2026. Dangers of injectable peptides and other unregulated “biohacking” drugs. Mo Med. PubMed 42757290
- Hailu KT, Abriha FN, Duguma YM, et al. 2026. Unregulated peptide use in the age of biohacking: digital promotion, gray-market access, and emerging public health risks. Cureus. PubMed 42437212
- University of Arkansas. Impact of BPC-157 on recovery from rotator cuff repair surgery. ClinicalTrials.gov NCT07803250
Change log
2026-10-26: links to related entries added; no change to the facts.
2026-10-18: removed ClinicalTrials.gov records NCT07437586 and NCT07437547, whose sponsor posts example records; registered trials now GHK-Cu 1, not yet recruiting (NCT07706361), and BPC-157 3, none with posted results; reviewed by the editorial team.
2026-10-18: diabetic ulcer infection figures limited to the ulcers treated right after debridement, as in Mulder 1994; reviewed by the editorial team.
2026-10-13: links corrected (a link inside a citation or on a generic word removed); no change to the facts.
2026-10-12: links to related entries added; no change to the facts.
2026-10-05: status box re-checked; GHK-Cu registered trials corrected to 2 (NCT07437586, NCT07706361); reviewed by the editorial team.
2026-09-30: status box updated with the FDA advisory committee vote / next regulatory step (Study loop L-2).
2026-09-30: first published after review by the editorial team.